Secukinumab and Latex Allergies: Don't trust your EMR

Main Article Content

Yuhan David Gu
Vagelos College of Physicians and Surgeons, Columbia University, New York, (NY) USA

Hoyt Harris Reynolds
Department of Dermatology University of Alabama at Birmingham

Rebecca Kissel
Department of Dermatology University of Alabama at Birmingham

Boni E Elewski
Department of Dermatology University of Alabama at Birmingham

Keywords

biologics, drug reactions, psoriasis, latex allergy

Abstract

Abstract not available.

References

1. Johnson C , Zumwalt M, Anderson N. Latex hypersensitivity to injection devices for biologic therapies in psoriasis patients. Cutis. 2018;102(2):116-118.

2. Isabwe GAC et al. Hypersensitivity reactions to therapeutic monoclonal antibodies: Phenotypes and endotypes. The Journal of Allergy and Clinical Immunology. 2018;142(1):159-170. https://doi.org/10.1016/j.jaci.2018.02.018

3. Roest MA, Shaw S, Orton DI. Insulin-injection-site reactions associated with type I Latex allergy. New England Journal of Medicine. 2003:348(3);265-266. https://doi.org/10.1056/NEJM200301163480320

4. Dexheimer JW, Kirkendall ES, Kouril M, et al. The Effects of Medication Alerts on Prescriber Response in a Pediatric Hospital. Appl Clin Inform. 2017;8(2):491–501. https://doi:10.4338/ACI-2016-10-RA-0168

5. Eslami S, Abu-Hanna A, de Keizer NF. Evaluation of outpatient computerized physician medication order entry systems: a systematic review. J Am Med Inform Assoc. 2007;14(4):400–406. https://doi:10.1197/jamia.M2238

Article Sidebar

PDF
Published
Jan 28, 2020
DOI https://doi.org/10.25251/skin.4.1.18

Article Details

How to Cite
Gu, Y. D., Reynolds, H. H., Kissel, R., & Elewski, B. E. (2020). Secukinumab and Latex Allergies: Don’t trust your EMR. SKIN The Journal of Cutaneous Medicine, 4(1), 97–99. https://doi.org/10.25251/skin.4.1.18
Issue
Vol. 4 No. 1 (2020): January Issue & Poster Presentations (2020 Winter Clinical Dermatology Conference®)
Section
Short Communications
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.